Abstract: A cancer therapeutic agent comprising a combination of compound A described below, or a pharmaceutically acceptable salt thereof, and compound B described below, or a pharmaceutically acceptable salt thereof: Compound A represented by the formula of claim 1 and Compound B represented by: at least one type of compound selected from the group consisting of a platinum-type anticancer compound, selected from the group consisting of cisplatin carboplatin, oxaliplatin and nedaplatin; a gemcitabine-type compound, selected from the group consisting of gemcitabine and Ara-C; a 5-FU-type compound, selected from the group consisting of 5-FU, doxifluridine, UFT, carmofur, S-1, and capecitabine; a texane-type compound, selected from the group consisting of Taxol, Taxotere, IDN 5109, BMS 188797 BMS 184476 paclitaxel and docetaxel; a vinca alkaloid-type compound, selected from the group consisting of vinorelbine, vincristine, vinblastine, and videsine; an anticancer tyrosine kinase inhibitor compound, and an anticancer mo

Abstract: A cancer therapeutic agent according to the present invention comprises a combination of compound A described below, or a pharmaceutically acceptable salt thereof, and compound B described below, or a pharmaceutically acceptable salt thereof: Compound A: compound A1 represented by formula (1) below, or water-soluble prodrug A2 thereof; Compound B: at least one type of compound selected from the group consisting of a platinum-type anticancer compound, a gemcitabine-type compound, a 5-FU-type compound, a taxane-type compound, a vinca alkaloid-type compound, an anticancer tyrosine kinase inhibitor compound, and an anticancer monoclonal antibody; (wherein, R11 represents a hydrogen atom, a halogen atom or a C1-C6 alkyl group; R12 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group, or a hydroxyl group; R21 represents a hydrogen atom or a C1-C10 alkyl group which may comprise one to three substituents selected from Group B described below: Group B: a C1-C6 alkoxy group, a hydroxy group,

Abstract: Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer of the present invention comprise a water-soluble prodrug represented by formula 1 described below, or a pharmaceutically acceptable salt, or a hydrate or solvate of the prodrug or pharmaceutically acceptable salt, (wherein, R1 represents a hydrogen atom, or a C1-C6 alkyl group; W represents a divalent group comprising a tertiary amino group or a divalent group comprising a sulfonyl group, and Y represents a residue of a compound represented by Y—OH comprising an alcoholic hydroxyl group, wherein said Y—OH is a camptothecin, a taxane, or an anticancer nucleotide).